Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy

P.W. Ruff, D.R. Ferry, R. Lakom, J. Prausová, Guy Van Hazel, P.M.G. Hoff, D. Cunningham, D.L. Arnold, H.J. Schmoll -, V.M. Moiseyenko, J.J. Mckendrick, A.J. Ten Tije, R.L. Vishwanath, P. Bhargava, S. Chevalier, T. Macarulla, E.V.D.G. Van Cutsem

    Research output: Contribution to journalArticle

    11 Citations (Scopus)

    Abstract

    ©2014 The Authors. Published by Elsevier Ltd. Background Patients with metastatic colorectal cancer (mCRC) previously-treated with oxaliplatin benefit significantly from the addition of aflibercept to FOLFIRI in relation to overall survival, progression-free survival and response rate. Patients and methods The results for efficacy and safety over the time course of the VEGF Trap (aflibercept) with irinotecan in colorectal cancer after failure of oxaliplatin regimen trial were analysed based on data from 1226 patients randomised to receive FOLFIRI plus either aflibercept (n = 612) or placebo (n = 614). Hazard ratios (HR) by 6-month time period were estimated using a piecewise Cox proportional hazard model. Severity of adverse events (AEs) was graded using National Cancer Institute Common Terminology Criteria, version 3.0. Results The estimated probabilities of survival were 38.5% versus 30.9% at 18 months, 28.0% versus 18.7% at 24 months and 22.3% versus 12.0% at 30 months, for the aflibercept- and placebo-treated arms, respectively. The proportional improvement in the HR over time was consistent with the survival probability results; survival at 24 months was improved by 50% and almost doubled at 30 months. The majority of worst-grade AEs occurred within the first four cycles of treatment and in a small percent of treatment cycles and were mostly reversible. Common chemotherapy- and anti-vascular epithelial growth factor (VEGF)-associated AEs occurred rarely and in a small proportion of cycles with the majority being of single occurrence. Conclusions The addition of aflibercept to FOLFIRI showed a continued and persistent improvement in overall survival over time in patients with mCRC. Although grade 3-4 AEs were more frequent in the aflibercept arm, they occurred in early treatment cycles and decreased sharply following initial presentation.
    Original languageEnglish
    Pages (from-to)18-26
    JournalEuropean Journal of Cancer
    Volume51
    Issue number1
    DOIs
    Publication statusPublished - 2015

    Fingerprint Dive into the research topics of 'Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy'. Together they form a unique fingerprint.

  • Cite this

    Ruff, P. W., Ferry, D. R., Lakom, R., Prausová, J., Van Hazel, G., Hoff, P. M. G., Cunningham, D., Arnold, D. L., Schmoll -, H. J., Moiseyenko, V. M., Mckendrick, J. J., Ten Tije, A. J., Vishwanath, R. L., Bhargava, P., Chevalier, S., Macarulla, T., & Van Cutsem, E. V. D. G. (2015). Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. European Journal of Cancer, 51(1), 18-26. https://doi.org/10.1016/j.ejca.2014.10.019